Cencora, Inc. (NYSE:COR) Receives $238.78 Consensus PT from Analysts

Shares of Cencora, Inc. (NYSE:COR) have been given an average rating of “Moderate Buy” by the nine ratings firms that are presently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $238.78.

Several equities analysts recently weighed in on the stock. StockNews.com lowered shares of Cencora from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 2nd. Citigroup increased their price target on shares of Cencora from $265.00 to $280.00 and gave the company a “buy” rating in a research report on Tuesday, April 30th. Robert W. Baird increased their price target on shares of Cencora from $280.00 to $285.00 and gave the company an “outperform” rating in a research report on Tuesday, July 9th. Finally, SVB Leerink restated an “outperform” rating and set a $275.00 price target on shares of Cencora in a research report on Thursday, June 27th.

Insider Transactions at Cencora

In other news, Director Dermot Mark Durcan purchased 500 shares of the stock in a transaction dated Friday, May 24th. The shares were purchased at an average cost of $218.58 per share, with a total value of $109,290.00. Following the completion of the acquisition, the director now owns 21,876 shares in the company, valued at approximately $4,781,656.08. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the firm’s stock in a transaction that occurred on Wednesday, May 22nd. The shares were sold at an average price of $215.12, for a total value of $399,991,976.80. Following the sale, the insider now directly owns 24,418,171 shares of the company’s stock, valued at $5,252,836,945.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Dermot Mark Durcan bought 500 shares of the stock in a transaction that occurred on Friday, May 24th. The stock was bought at an average cost of $218.58 per share, for a total transaction of $109,290.00. Following the completion of the purchase, the director now directly owns 21,876 shares of the company’s stock, valued at $4,781,656.08. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 1,899,112 shares of company stock valued at $408,654,376. 15.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Cencora

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. purchased a new stake in Cencora in the fourth quarter valued at approximately $4,212,508,000. Price T Rowe Associates Inc. MD purchased a new stake in Cencora in the first quarter valued at approximately $2,183,619,000. JPMorgan Chase & Co. purchased a new stake in Cencora in the first quarter valued at approximately $1,199,695,000. Boston Partners bought a new position in Cencora during the first quarter valued at approximately $1,001,269,000. Finally, Capital Research Global Investors bought a new position in Cencora during the first quarter valued at approximately $650,424,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Stock Performance

NYSE COR opened at $227.62 on Tuesday. Cencora has a 1 year low of $171.65 and a 1 year high of $246.75. The company has a debt-to-equity ratio of 3.41, a current ratio of 0.89 and a quick ratio of 0.53. The firm has a market cap of $45.40 billion, a price-to-earnings ratio of 24.90, a PEG ratio of 1.58 and a beta of 0.45. The company has a fifty day moving average price of $226.96 and a 200-day moving average price of $230.60.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, May 1st. The company reported $3.80 earnings per share for the quarter, beating the consensus estimate of $3.65 by $0.15. The company had revenue of $68.41 billion during the quarter, compared to analyst estimates of $70.60 billion. Cencora had a net margin of 0.67% and a return on equity of 268.67%. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.50 earnings per share. As a group, equities research analysts predict that Cencora will post 13.46 EPS for the current fiscal year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 24th. Shareholders of record on Friday, May 10th were issued a dividend of $0.51 per share. This represents a $2.04 annualized dividend and a yield of 0.90%. The ex-dividend date was Thursday, May 9th. Cencora’s dividend payout ratio (DPR) is presently 22.32%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.